RIG012 is a potent RIG-I inhibitor with an IC 50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > IFNAR
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。